Used to treat hypercholesterolemia and to prevent cardiovascular disease.
HMG CoA Reductase Inhibitor
Fluvastatin acts by competitively inhibiting HMG-CoA reductase, the enzyme for cholesterol synthesis. It reduces total cholesterol, triglycerides, LDL and VLDL concentrations in plasma. It also increases HDL concentrations.
Immediate Release Capsules: -Low-density lipoprotein cholesterol (LDL-C) reduction to a goal of 25% or greater: Initial dose of 40 mg orally once a day in the evening or 40 mg orally twice a day -LDL-C reduction to a goal of less than 25%: Initial dose of 20 mg orally once a day -Maintenance dose: 20 mg to 80 mg per day. Extended Release Tablets: 80 mg orally once a day, at any time of day
Cyclosporine: Combination increases Fluvastatin exposure. Limit dose to 20 mg
Fluconazole: Combination increases Fluvastatin exposure. Limit dose to 20 mg
Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (≥1 g/day) of niacin increases the risk of adverse skeletal muscle effects.
Glyburide: Monitor blood glucose levels when Fluvastatin dose is changed
Phenytoin: Monitor plasma phenytoin levels when Fluvastatin treatment is initiated or when the dosage is changed
Warfarin and coumarin derivates: Monitor prothrombin times when Fluvastatin co-administration is initiated, discontinued, or the dosage changed.
Acute liver disease; unexplained persistently raised serum aminotransferase concentrations; porphyria; pregnancy; lactation. History of liver disease; high alcohol intake. Manage hypothyroidism adequately before starting treatment. Report unexplained muscle pain. Monitor LETs. Discontinue in case of marked or persistent increase in serum aminotransferase or creatine phosphokinase. Severe renal impairment.
GI disturbances; headache; skin rashes; dizziness; blurred vision; insomnia; dysgeusia; hepatitis; pancreatitis; hypersensitivity syndrome; myopathy; rhabdomyolysis w/ acute renal failure.
Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.Use in women who are or may become pregnant is contraindicated. Advice for mothers using Fluvastatin while breastfeeding. Includes possible effects on breastfed infants and lactation.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
.png&w=384&q=75)